RAUORA Trial: Cytisine vs varenicline for smoking cessation in New Zealand
RAUORA Trial is a study evaluating whether cytisine, a nicotinic acetylcholine receptor partial agonist (like varenicline) found in some plants is effective, safe and cost‐effectiveness compared with varenicline for smoking cessation in Māori and the whānau (extended family) of Māori.
Dr Subhash Pokhrel from Health Economics Theme is leading the economics component of the RAUORA trial. New Zealand (NZ) has a smoke‐free 2025 goal (i.e. < 5% of adults smoking by 2025). To achieve this goal, net smoking cessation rates need to increase substantially, particularly for Māori who, in 2016, comprised 14% of the NZ population, who have a high prevalence of daily smoking (33%) compared with the general population (14%). Consequently, Māori have high rates of smoking‐related disease, contributing to the 7–8‐year life‐expectancy gap between Māori and non‐Māori in NZ. Offering cytisine may be a potenially cost-effective strategy in achieving this goal.
This is a pragmatic, community-based, open-label randomized non-inferiority trial based in Lakes District Health Board region, NZ.
Cytisine versus varenicline for smoking cessation for Māori (the indigenous people of New Zealand) and their extended family: protocol for a randomized non‐inferiority trial